Duration of BTKi therapy correlates with time to next treatment in CLL | Kerry Rogers, MD | #ASH24

Duration of BTKi therapy correlates with time to next treatment in CLL | Kerry Rogers, MD | #ASH24
A Unique BTK Inhibitor, Pirtobrutinib for Patients with Pretreated CLL | Jeff Sharman, MD | #ASH24
Duvelisib + Venetoclax: A Time-Limited, All Oral Option for CLL | Jennifer Crombie, MD | #ASH24
Major side effects of CLL: what patients should prepare for
Managing the Caregiver Roles: Chef, Chauffeur, Secretary, and More
